Potent induction of trained immunity by Saccharomyces cerevisiae β-glucans.
Study Goal
The researchers aimed to determine whether a high-complexity blend of β-glucans from Saccharomyces cerevisiae could enhance trained immunity in human primary monocytes and reduce tumor growth in murine models of melanoma and bladder cell carcinoma.
Results Summary
The β-glucan blend demonstrated strong bioactivity, inducing trained immunity via multiple receptors and signaling pathways, leading to a robust secondary immune response. In vivo, pre-treatment significantly reduced tumor growth in mice, suggesting potential therapeutic applications. The study did not address long-term effects or human clinical outcomes.
Population
Human primary monocytes and murine models (mice) with melanoma and bladder cell carcinoma.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Candida albicans cell wall component β-glucan | increase | epigenetic and functional reprogramming of innate immune cells | innate immune cells | - | has been extensively studied for its ability to induce | #1 |
a high-complexity blend of two individual β-glucans from Saccharomyces cerevisiae | increase | strong bioactivity | - | - | possesses | #2 |
a high-complexity blend of two individual β-glucans from Saccharomyces cerevisiae | increase | trained innate immune response | human primary monocytes | - | resulting in an enhanced | #3 |
The training | neutral | the Dectin-1/CR3, TLR4, and MMR receptors, as well as the Raf-1, Syk, and PI3K downstream signaling molecules | - | - | required | #4 |
the components of this β-glucan preparation | increase | a robust secondary response upon an unrelated challenge | - | - | are able to act synergistically, causing | #5 |
pre-treatment of mice with the β-glucan preparation | decrease | tumor growth | in in-vivo murine models of melanoma and bladder cell carcinoma | - | led to a significant reduction in | #6 |
Candida albicans cell wall component β-glucan has been extensively studied for its ability to induce epigenetic and functional reprogramming of innate immune cells, a process termed trained immunity. We show that a high-complexity blend of two individual β-glucans from Saccharomyces cerevisiae possesses strong bioactivity, resulting in an enhanced trained innate immune response by human primary monocytes. The training required the Dectin-1/CR3, TLR4, and MMR receptors, as well as the Raf-1, Syk, and PI3K downstream signaling molecules. By activating multiple receptors and downstream signaling pathways, the components of this β-glucan preparation are able to act synergistically, causing a robust secondary response upon an unrelated challenge. In in-vivo murine models of melanoma and bladder cell carcinoma, pre-treatment of mice with the β-glucan preparation led to a significant reduction in tumor growth. These insights may aid in the development of future therapies based on β-glucan structures that induce an effective trained immunity response.